MDGL - NASDAQ

Madrigal Pharmaceuticals, Inc.

MDGL·NASDAQ

$488.15

+7.8%

HealthcareBiotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$11.25B

EPS-12.8500

P/E Ratio-37.99

Earnings Date08/04/2026

1.26B

Assets

21%

3Y+247.0%

5Y+339.0%

10Y+2957.0%

656.90M

Total Liabilities

128%

3Y+298.0%

5Y+1297.0%

10Y+13585.0%

602.69M

Total Equity

-20%

3Y+205.0%

5Y+151.0%

10Y+1555.0%

Madrigal Pharmaceuticals, Inc. Funding & Solvency Profile

MDGL · NASDAQ

Current Assets

Cash & Cash Equivalents198.69M

Net Receivables134.48M

Inventory74.84M

Other Current Assets52.89M

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment6.44M

Goodwill & Intangible Assets7.38M

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets6 M

Total Assets

1.26B

Financial Health Analysis

Current Ratio

4.01x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.09x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

935 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Madrigal Pharmaceuticals, Inc. Balance Sheet

MDGL • NASDAQ

Madrigal Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	198.7M	100M	99.9M	331.5M	36.3M	54M	46.7M	57.4M	148.6M	40.5M	35M	46M	48.5M	81.5M	30.1M	31.3M	44.2M	52M	115.6M	33.7M
Short-Term Investments	784.9M	826.2M	534.2M	27.2M	234.1M	230.1M	392.3M	426.3M	42.9M	0.0	31.6M	51.7M	43M	19.1M	9.7M	19.7M	0.0	21.5M	0.0	13.1M
Cash & Short-Term Investments	983.6M	926.3M	634.1M	358.8M	270.3M	284.1M	439M	483.7M	191.5M	40.5M	66.6M	97.7M	91.5M	100.6M	39.7M	51M	44.2M	73.6M	115.6M	46.8M
Net Receivables	134.5M	53.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3K	0.0	0.0	0.0	0.0	116K	0.0	16M	0.0	0.0
Accounts Receivables	134.5M	53.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16M	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3K	0.0	0.0	0.0	0.0	116K	0.0	0.0	0.0	0.0
Inventory	74.8M	34.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	1.3M	1M	1.2M	1.5M	485K	707K	50K	0.0	765K	786K	561K	431K	419K	1.5M	1.3M	263K
Other Current Assets	52.9M	18.8M	3.2M	2.6M	0.0	0.0	1.2M	1.5M	485K	0.0	0.0	1.7M	0.0	0.0	0.0	0.0	419K	151K	83K	540K
Total Current Assets	1.2B	1B	637.3M	361.4M	271.7M	285.2M	440.2M	485.2M	192M	41.2M	363.6K	99.3M	92.2M	101.4M	40.3M	51.5M	44.6M	91.2M	117M	47.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	6.4M	4.6M	3.3M	1.2M	1.6M	1.8M	1.9M	227K	301K	2.9K	420K	1M	1.6M	1.2M	1.4M	2.2M	4M	5.9M	5.6M	6.1M
Intangible Assets	7.4M	4.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	7.4M	4.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	305K	1.4M	458K	631K	366K	358K	103K	76K	1.1M
Total Non-Current Assets	13.8M	9.3M	3.3M	1.2M	1.6M	1.8M	1.9M	227K	301K	3K	420K	1.3M	3M	1.6M	2M	2.5M	4.3M	6M	5.7M	7.2M
Total Assets	1.3B	1B	640.5M	362.6M	273.3M	287M	442.1M	485.4M	192.3M	41.2M	68.2M	100.7M	95.2M	103M	42.3M	54.1M	48.9M	97.3M	122.6M	54.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	48.9M	43.6M	28M	23.8M	21.4M	1M	1.2M	2.5M	1.9M	762K	602.3K	3.1M	6.6M	5.7M	3.5M	1.9M	4M	3.3M	2.5M	2.6M
Accounts Payable	48.9M	43.6M	28M	23.8M	21.4M	1M	1.2M	2.5M	1.9M	762K	102.3K	3.1M	6.6M	5.7M	3.5M	1.9M	4M	3.3M	2.5M	2.6M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	89.7M	73M	76.6M	48.3M	40.5M	20.9M	4.2M	8.1M	4M	79.5K	3.9M	3.1M	3.3M	2.9M	6.7M	2.8M	759K	9.2M	1.2M
Short Term Debt	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.1M	9.3M	9.5M	7.9M	4.2M	0.0	0.0	2.2M	2.4M	2.3M
Capital Lease Obligations (Current)	0.0	983K	527K	602K	410K	318K	315K	0.0	0.0	0.0	0.0	0.0	42K	13K	12K	201K	1.3M	2.2M	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-43K	-42K	-42K	-13K	-12K	4.6M	4.6M	12.6M	5.4M	457K
Other Current Liabilities	260.4M	35M	17M	14.9M	6.8M	4.7M	2.8M	1.8M	0.0	0.0	43K	14.6M	12.9M	6.6M	4.5M	3.3M	3.8M	12.3M	1.3M	4.9M
Total Current Liabilities	310.3M	169.3M	118.5M	115.9M	76.8M	46.6M	25.1M	8.4M	10.1M	4.8M	49.3M	30.9M	32.2M	23.5M	15.1M	16.7M	16.5M	33.3M	20.8M	11.5M
NON-CURRENT LIABILITIES
Long Term Debt	346.6M	117.6M	115.5M	49.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6M	13.8M	4.5M	12.4M	11.7M	0.0	6.3M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	6.7M	114.4M	74.2M	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-26K	-799K	-114.4M	-74.2M	0.0
Other Non-Current Liabilities	-6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41.8M
Total Non-Current Liabilities	346.6M	118.6M	116.7M	49.3M	387K	468K	361K	0.0	0.0	0.0	0.0	4.7M	13.9M	4.5M	12.4M	13.9M	7.5M	122.7M	77M	45M
Capital Lease Obligations	6.7M	2M	1.7M	602K	797K	786K	676K	0.0	0.0	0.0	43K	85K	127K	14K	26K	227K	2.1M	2M	2.8M	3.2M
Total Liabilities	656.9M	287.9M	235.2M	165.2M	77.2M	47M	25.5M	8.4M	10.1M	4.8M	17.8M	35.5M	46.1M	28M	27.6M	30.6M	24M	156M	97.8M	56.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	319K	31K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41.8M
Common Stock	2K	2K	2K	2K	2K	2K	2K	2K	1K	1.2K	14K	11K	9K	7K	5K	4K	3K	3K	3K	2K
Additional Paid-In Capital	2.7B	2.6B	1.7B	1.2B	863.5M	665.4M	639.6M	616.6M	288.8M	111.7M	6.2K	702.7M	600.5M	536.3M	413.2M	374.5M	338.5M	333.9M	324.9M	234.8M
Retained Earnings	-2.1B	-1.8B	-1.3B	-962.7M	-667.3M	-425.5M	-223.2M	-139.3M	-106.5M	-75.3M	-706.2M	-637.6M	-551.4M	-461.2M	-398.4M	-351.1M	-313.6M	-392.7M	-300.1M	-236.6M
Accumulated Other Comprehensive Income/Loss	873K	468K	468K	-32K	-80K	47K	216K	-319K	-31K	25.4K	4K	4K	17K	2K	3K	-3K	-16M	15K	-11.5M	2K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-41.8M
Total Stockholders' Equity	602.7M	754.4M	405.3M	197.4M	196.1M	240M	416.6M	477M	182.3M	36.4M	50.4M	65.1M	49.1M	75.1M	14.8M	23.5M	24.9M	-58.8M	24.9M	-1.7M
Total Equity	602.7M	754.4M	405.3M	197.4M	196.1M	240M	416.6M	477M	182.3M	36.4M	50.4M	65.1M	49.1M	75.1M	14.8M	23.5M	24.9M	-58.8M	24.9M	-1.7M
SUMMARY
Total Liabilities & Equity	1.3B	1B	640.5M	362.6M	273.3M	287M	442.1M	485.4M	192.3M	41.2M	68.2M	100.7M	95.2M	103M	42.3M	54.1M	48.9M	97.3M	122.6M	54.8M
Total Investments	784.9M	826.2M	534.2M	27.2M	234.1M	230.1M	392.3M	426.3M	42.9M	0.0	31.6M	51.7M	43M	19.1M	9.7M	19.7M	0.0	21.5M	0.0	13.1M
Total Debt	354.4M	119.6M	117.2M	49.9M	797K	786K	676K	0.0	0.0	0.0	4.7M	13.9M	23.4M	12.4M	16.6M	11.9M	2.1M	10.5M	5.2M	5.5M
Net Debt	155.7M	19.6M	17.3M	-281.7M	-35.5M	-53.2M	-46M	-483.7M	-191.5M	-40.5M	-30.3M	-32.1M	-25.1M	-69.1M	-13.4M	-19.4M	-42.1M	-41.6M	-110.4M	-28.2M
Shares Outstanding	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162	22,180,162

SEC Filings

MDGL - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 22, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 11, 2025	December 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 304 filings

Related Guides

Blog Categories

Continue your MDGL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.